Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Subsequent Events (Details Textual)

Note 11 - Subsequent Events (Details Textual)	Aug. 07, 2024 $ / shares shares	Jul. 23, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Jun. 30, 2024 $ / shares	Dec. 31, 2023 $ / shares
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001	$ 0.001
Pieris Pharmaceutical Stockholders [Member] \| Forecast [Member]
Ownership Percentage			18.00%
Pavella Stockholders [Member] \| Forecast [Member]
Ownership Percentage			82.00%
Subsequent Event [Member] \| Series F Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.01
Preferred Stock, Voting Rights, Number of Votes Per Share	25,000,000
Subsequent Event [Member] \| Series F Preferred Stock [Member] \| Board of Directors Chairman [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares	1
Shares Issued, Price Per Share (in dollars per share) \| $ / shares	$ 1
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001
Subsequent Event [Member] \| Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares		2,592,585
Class of Warrant or Right, Exercise Price, Subtracted Amount From Purchase Price, Per Share		$ 0.001
Class of Warrant or Right, Maximum Beneficial Percentage Ownership If Exercised		4.99%
Class of Warrant or Right, Maximum Percentage of Shares Outstanding if Exercised		9.99%
Class of Warrant or Right, Maximum Percentage Beneficial Ownership With Notice		19.99%
Subsequent Event [Member] \| Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares		3,154,241
Shares Issued, Price Per Share (in dollars per share) \| $ / shares		$ 13.7299
Shares Issued, Price Per Share, Multiplier		0.315478
Proceeds from Issuance or Sale of Equity		$ 78,900,000
Subsequent Event [Member] \| Palvella [Member]
Contingency, Termination Fee Payable			$ 1,000,000
Contingency, Termination Fee, Receivable			$ 2,000,000
Subsequent Event [Member] \| Palvella Merger [Member]
Merger, Cash Threshold		11,000,000
Subsequent Event [Member] \| Palvella Merger [Member] \| Palvella [Member]
Company Valuation		95,000,000
Subsequent Event [Member] \| Palvella Merger [Member] \| Pieris Pharmaceutical Stockholders [Member]
Company Valuation		$ 21,000,000